Concord Drugs Reports Q3 FY 2024-25 Results Amid Mixed Financial Indicators

Jan 13 2025 08:00 AM IST
share
Share Via
Concord Drugs has released its financial results for Q3 of fiscal year 2024-25, highlighting significant improvements in operating profit and profit margins, alongside increased earnings per share. However, the company faced challenges with net sales, which declined year-on-year, marking the lowest level in five quarters.
Concord Drugs, a microcap company in the pharmaceuticals and drugs industry, has reported its financial results for the third quarter of fiscal year 2024-25. The results, declared on January 11, 2025, reflect an adjustment in evaluation, with the company's score shifting from 7 to 4 over the past three months.

While the overall assessment indicates stagnation, several key metrics reveal noteworthy developments. The operating profit (PBDIT) reached Rs 1.39 crore, representing the highest figure in the last five quarters, accompanied by an operating profit margin of 12.87%, also the best in this timeframe. Profit before tax (PBT) and profit after tax (PAT) both achieved their highest levels in five quarters, at Rs 0.53 crore and Rs 0.23 crore, respectively. Furthermore, earnings per share (EPS) increased to Rs 0.23, suggesting enhanced profitability for shareholders.

On the other hand, net sales encountered difficulties, declining to Rs 10.80 crore, which marks a year-on-year decrease of 15.49% and the lowest figure in the last five quarters. This trend in sales points to challenges that may impact the company's near-term outlook.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News